Key facts
- It has raised $43.1M across 2 recorded rounds; the latest was Early Stage VC ($22.7M) in Apr 2022.
- Notable investors include Insight Partners (New York), NFX, iAngels, Mayo Clinic, Mayo Clinic Ventures — 14 tracked in total.
- Theator has filed 4 Form Ds with the SEC since 2021, most recently Apr 2022 ($22.7M sold to 9 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Theator
Funding rounds
2 roundsAbout Theator
Developer of a surgical intelligence platform designed to provide surgeons with decision support tools. The company uses artificial intelligence and computer vision to extract and annotate key moments from real-world procedures, enabling medical practitioners to gain scientific insight into their performances and those of surgeons worldwide.
- Sector
- Healthcare
- HQ
- Palo Alto, CA, United States
- Founded
- 2018
- Employees
- 56
- Website
- theator.io/
- Ownership
- Privately Held (backing)
Theator doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Theator shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Theator in its N-PORT filings yet. We sweep new filings monthly.